Capecitabine

Generic Name
Capecitabine
Brand Names
Ecansya, Xeloda, Capecitabine Medac, Ecansya (previously Capecitabine Krka), Capecitabine Accord, Capecitabine Teva
Drug Type
Small Molecule
Chemical Formula
C15H22FN3O6
CAS Number
154361-50-9
Unique Ingredient Identifier
6804DJ8Z9U
Background

Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.

Indication

Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemother...

Associated Conditions
Advanced or Metastatic Breast Cancer, Carcinoma of Gallbladder, Cholangiocarcinoma, Hepatocellular Carcinoma, Locally Advanced Rectal Cancer (LARC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancers, Metastatic Neuroendocrine Tumors, Pancreatic Adenocarcinoma, Pancreatic Cancer, Advanced or Metastatic, Platinum-resistant Epithelial Ovarian Cancer, Refractory Fallopian Tube Carcinoma, Stage III Colon Cancer, Unresectable or Metastatic Colorectal Cancer, Metastatic pancreatic endocrine carcinoma, Refractory peritoneal cancer, Refractory, metastatic Colorectal carcinoma, Unresectable, metastatic Esophageal Cancer, Unresectable, metastatic Gastric Cancer, Unresectable, metastatic Gastroesophageal Junction Cancer
Associated Therapies
Chemotherapy
Clinical Trials
Related News

Chemotherapy Plus EGFR Monoclonal Antibody in Patients With Liver Metastases From Colorectal Cancer With ctDNA Superselective Negative Genes

First Posted Date
2024-07-08
Last Posted Date
2024-07-08
Lead Sponsor
Fujian Cancer Hospital
Target Recruit Count
33
Registration Number
NCT06490913

The Sagittarius Trial

First Posted Date
2024-07-08
Last Posted Date
2024-11-11
Lead Sponsor
IFOM ETS - The AIRC Institute of Molecular Oncology
Target Recruit Count
700
Registration Number
NCT06490536
Locations
🇮🇹

Istituto Clinico Humanitas, Rozzano, Milano, Italy

🇮🇹

Istituto di Candiolo, Candiolo, Torino, Italy

🇮🇹

Azienda Sanitaria Locale di Biella, Biella, Italy

and more 11 locations

Substudy 06C: A Study of Sacituzumab Tirumotecan (MK-2870) With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

First Posted Date
2024-06-24
Last Posted Date
2024-12-02
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
130
Registration Number
NCT06469944
Locations
🇺🇸

University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 6927), Tucson, Arizona, United States

🇧🇷

Liga Norte Riograndense Contra o Câncer ( Site 6303), Natal, Rio Grande Do Norte, Brazil

🇩🇪

Facharztzentrum Eppendorf-Facharztzentrum Eppendorf ( Site 6807), Hamburg, Germany

and more 16 locations

Irinotecan Hydrochloride Liposome Combined With Capecitabine and Lenvatinib in Patients With Biliary Tract Carcinoma

First Posted Date
2024-06-18
Last Posted Date
2024-06-18
Lead Sponsor
Yunpeng Liu
Target Recruit Count
30
Registration Number
NCT06463548
Locations
🇨🇳

The First Hospital of China Medical University, Shenyang, China

Short-course Radiotherapy Combined With CAPOX and PD-1 Antibody Versus Long-course Chemoradiotherapy Combined With CAPOX for Early Low-lying Rectal Cancer

First Posted Date
2024-06-17
Last Posted Date
2024-06-17
Lead Sponsor
Fudan University
Target Recruit Count
134
Registration Number
NCT06462053
Locations
🇨🇳

Fudan University Shanghai Cancer Center, Shanghai, China

Short-course Radiotherapy Combined With CapeOx and PD-1 Inhibitor After Local Excision for High-risk Early Rectal Cancer (TORCH-LE)

First Posted Date
2024-06-12
Last Posted Date
2024-06-13
Lead Sponsor
Fudan University
Target Recruit Count
60
Registration Number
NCT06455124
Locations
🇨🇳

Fudan University Shanghai Cancer Center, Shanghai, China

Neoadjuvant Immunotherapy Plus Chemotherapy in Borrmann Type 4 and Large Type 3 Gastric Cancer

First Posted Date
2024-06-11
Last Posted Date
2024-06-11
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
53
Registration Number
NCT06451211
Locations
🇨🇳

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid Tumors

First Posted Date
2024-06-06
Last Posted Date
2024-06-06
Lead Sponsor
Qilu Pharmaceutical Co., Ltd.
Target Recruit Count
360
Registration Number
NCT06446388
Locations
🇨🇳

Beijing Cancer Hospital, Beijing, Beijing, China

A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

First Posted Date
2024-05-30
Last Posted Date
2024-12-18
Lead Sponsor
Jazz Pharmaceuticals
Target Recruit Count
550
Registration Number
NCT06435429
Locations
🇺🇸

USC-Norris Comprehensive Cancer Center - Investigational Drug Service IDS, Los Angeles, California, United States

🇺🇸

Medstar Georgetown University Hospital, Washington, District of Columbia, United States

🇺🇸

Washington Cancer Center, Washington, District of Columbia, United States

and more 38 locations

Clinical Study of Irinotecan Hydrochloride Liposome Combined With Capecitabine for Second-line Treatment in Patients With Advanced or Metastatic Biliary Tract Carcinoma

First Posted Date
2024-05-28
Last Posted Date
2024-05-28
Lead Sponsor
Ba Yi
Target Recruit Count
20
Registration Number
NCT06430827
Locations
🇨🇳

Peking Union Medicalcollege Hospital, Beijing, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy